Back to Search Start Over

Reversal of the CD8 + T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways.

Authors :
Li J
Huang HH
Tu B
Zhou MJ
Hu W
Fu YL
Li XY
Yang T
Song JW
Fan X
Jiao YM
Xu RN
Zhang JY
Zhou CB
Yuan JH
Zhen C
Shi M
Wang FS
Zhang C
Source :
Frontiers in immunology [Front Immunol] 2021 Jun 10; Vol. 12, pp. 687296. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021).
Publication Year :
2021

Abstract

Background: Targeting immune checkpoints for HIV treatment potentially provides a double benefit resulting from the ability to restore viral-specific CD8 <superscript>+</superscript> T-cell functions and enhance HIV production from reservoir cells. Despite promising pre-clinical data, PD-1 blockade alone in HIV-1-infected patients with advanced cancer has shown limited benefits in controlling HIV, suggesting the need for additional targets beyond PD-1. CD39 and PD-1 are highly co-expressed on CD8 <superscript>+</superscript> T cells in HIV-1 infection. However, the characteristics of CD39 and PD-1 dual-positive CD8 <superscript>+</superscript> T-cell subsets in chronic HIV-1 infection remain poorly understood.<br />Methods: This study enrolled 72 HIV-1-infected patients, including 40 treatment naïve and 32 ART patients. A total of 11 healthy individuals were included as controls. Different subsets of CD8 <superscript>+</superscript> T cells defined by CD39 and/or PD-1 expression were studied by flow cytometry. The relationships between the frequencies of the different subsets and parameters indicating HIV-1 disease progression were analyzed. Functional (i.e., cytokine secretion, viral inhibition) assays were performed to evaluate the impact of the blockade of adenosine and/or PD-1 signaling on CD8 <superscript>+</superscript> T cells.<br />Results: The proportions of PD-1 <superscript>+</superscript> , CD39 <superscript>+</superscript> , and PD-1 <superscript>+</superscript> CD39 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells were significantly increased in treatment naïve patients but were partially lowered in patients on antiretroviral therapy. In treatment naïve patients, the proportions of PD-1 <superscript>+</superscript> CD39 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells were negatively correlated with CD4 <superscript>+</superscript> T-cell counts and the CD4/CD8 ratio, and were positively correlated with viral load. CD39 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells expressed high levels of the A2A adenosine receptor and were more sensitive to 2-chloroadenosine-mediated functional inhibition than their CD39 <superscript>-</superscript> counterparts. In vitro , a combination of blocking CD39/adenosine and PD-1 signaling showed a synergic effect in restoring CD8 <superscript>+</superscript> T-cell function, as evidenced by enhanced abilities to secrete functional cytokines and to kill autologous reservoir cells.<br />Conclusion: In patients with chronic HIV-1 infection there are increased frequencies of PD-1 <superscript>+</superscript> , CD39 <superscript>+</superscript> , and PD-1 <superscript>+</superscript> CD39 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells. In treatment naïve patients, the frequencies of PD-1 <superscript>+</superscript> CD39 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells are negatively correlated with CD4 <superscript>+</superscript> T-cell counts and the CD4/CD8 ratio and positively correlated with viral load. Combined blockade of CD39/adenosine and PD-1 signaling in vitro may exert a synergistic effect in restoring CD8 <superscript>+</superscript> T-cell function in HIV-1-infected patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Li, Huang, Tu, Zhou, Hu, Fu, Li, Yang, Song, Fan, Jiao, Xu, Zhang, Zhou, Yuan, Zhen, Shi, Wang and Zhang.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
34177939
Full Text :
https://doi.org/10.3389/fimmu.2021.687296